Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337440 | 1.00 | GSK3B (0.54) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL17490471 | 0.89 | DYRK1A (0.45) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL28987624 | 0.88 | DYRK1A (0.43) | GSK3BCDK1CCNB1DYRK1BKDR | |
| SCHEMBL30337437 | 0.88 | DYRK1A (0.43) | GSK3BCDK1CCNB1DYRK1BKDR | |
| SCHEMBL30337352 | 0.86 | DYRK1A (0.42) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL28987589 | 0.86 | DYRK1A (0.42) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL18979170 | 0.86 | DYRK1A (0.42) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL30337214 | 0.85 | DYRK1A (0.50) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL28987580 | 0.85 | DYRK1A (0.41) | GSK3BCDK1CCNB1DYRK1BAURKA | |
| SCHEMBL30337183 | 0.85 | DYRK1A (0.41) | GSK3BCDK1CCNB1DYRK1BAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| CN-115974845-A | Preparation method of oxitinib intermediate | 奥锐特药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-RE48687-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-RE48687-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-107382975-B | Crystalline forms of fluoroarylamine pyrimidine compounds and salts thereof | 齐鲁制药有限公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3181560-B1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3181560-B1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-10072002-B2 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2018-09-11 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| EP-3181560-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181560-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016015453-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 上海艾力斯医药科技有限公司 | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | EGFR, ERBB2, ERBB4 | GSK3B 1952/4885CDK1 37/4885CCNB1 25/4885 |
| US-10072002-B2 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | EGFR, ERBB2, ERBB4 | GSK3B 1952/4885CDK1 37/4885CCNB1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.